Bluejay Therapeutics https://validator.w3.org/feed/docs/rss2.html Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D Preclinical characterization of BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor for the treatment of MASH Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex (R) (Bulevirtide) for Chronic Hepatitis D  Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Characterization of BJT-778, an Anti-HBsAg Neutralizing Monoclonal Antibody for Treatment of Hepatitis B Virus and Hepatitis D Virus Infections BJT-778, Anti-HBsAg Monoclonal Antibody, Achieved 100% Virologic Response in Subjects with Chronic Hepatitis D (CHD): Phase 2 Study Results Characterization of Cavrotolimod, a TLR9 Agonist for the Treatment of Chronic Hepatitis B Uptake and T Cell Stimulation by BJT-778-HBsAg Immune Complexes: Insights into Anti-HBs Monoclonal Antibody Function Safety, Tolerability, and Pharmacokinetics of BJT-778, a Monoclonal Antibody for Treatment of Chronic Hepatitis B and Chronic Hepatitis D, Following Single Ascending Doses in Healthy Volunteers Rapid Reductions of HDV RNA and ALT with the Monoclonal Antibody, BJT-778: Results from a Phase 2 Study Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 Bluejay Therapeutics’ Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response and up to 82% Combined Endpoint of Virologic Response and ALT Normalization at Week 48 in Phase 2 Study in Chronic Hepatitis D (CHD) Bluejay Therapeutics Announces Upcoming Presentation of Preclinical Data in  Metabolic Dysfunction-Associated Steatohepatitis (MASH) at European Association for the Study of the Liver (EASL) Congress 2025  Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta Corporate Presentation: 43rd Annual J.P. Morgan Healthcare Conference Bluejay Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024 Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response in Patients with Chronic Hepatitis D: On Treatment Week 48 Phase 2 Study Results Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)  Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline Bluejay: Combining HBV Therapies To Reach a Functional Cure Lonza and Bluejay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting Chronic HBV Infection Bluejay Therapeutics to Present at the 2nd Global IR @ JPM Conference 2022 Global IR @ JPM Virtual Demo Day Tickets, Wed, Jan 19, 2022 at 7:00 pm | Eventbrite Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D Bluejay Therapeutics Raises $41 Million in Series B Round to Drive Clinical Trials in Chronic Hepatitis Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development New home page